1 FTSE 100 stock I’d buy today and it’s not Lloyds or Rolls-Royce

Lloyds and Rolls-Royce get more attention than most FTSE 100 stocks, but they’re not the first place I’d look to invest in today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Lloyds and Rolls-Royce are two of the most traded companies in the UK at the moment. Yet, despite all the attention, neither would be the first FTSE 100 stock I’d put money into today. 

Don’t get me wrong, I like these firms and own shares in both, but they each have issues. Lloyds may look cheap but it’s traded sideways for years. Rolls-Royce has had a good year but is still not profitable and is some way from paying a dividend. 

A better place for my money would be a growing company with no red flags, and for that, I’m looking at pharmaceutical firm AstraZeneca (LSE: AZN). I think it might be the best stock to buy on the Footsie right now. 

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Unlike those other two, AstraZeneca is a company squarely on the rise. Last year’s revenue was up 25% and earnings-per-share (EPS) was up 33%. Analysts expect this to continue, with some predicting 20% EPS growth for the next five years.  

Source: AstraZeneca

This growth can be put down to CEO Pascal Soriot. He took the reins in 2012 with a pledge to focus on R&D and innovation. He’s clearly doing something right as the shares are up 282% and AstraZeneca is now the biggest firm on the entire FTSE 100. 

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL7 Aug 20127 Aug 2023Zoom ▾201320142015201620172018201920202021202220232014201420162016201820182020202020222022www.fool.co.uk

Innovation

The focus on innovation looks a very good move in hindsight. A pharma firm lives and dies on its drugs pipeline, and in that regard, it’s in a great spot with plenty of big money-spinners. 

Here are the full-year results of five medicines from 2022:

  • Lung cancer medicine Tagrisson saw 15% growth to $5.4bn
  • Cancer medicine Imfinzi enjoyed 21% growth to $2.7bn
  • Diabetes drug Farxiga saw 56% growth to $4.4bn
  • Asthma drug Symbicort recorded a 2% decrease to $2.5bn
  • Rare disease drug Ultomiris reported 42% growth to $2bn

This isn’t the end of it either. Another 178 drugs are in development, which shows there’s no slowdown in the firm’s ability to create revenue-generating medicines. I’d have to say the future looks bright here.

The icing on the cake is the valuation. It’s true that AstraZeneca has looked expensive in recent years, touching a price-to-earnings ratio of nearly 100 only in the last year. But the backwards facing P/E is now just 34 and the forward P/E is only 18. That strikes me as very reasonable for a business that’s growing this much. 

US rival Eli Lilly looks much more expensive with a forward P/E of 52. And looking at UK competitors, GSK does have a lower P/E ratio of 9 but with prospects that aren’t nearly as good.

A buy?

In terms of risks, the firm does carry debt. The debt-to-equity of about 85% is high and may mean make it harder to fund future research, especially with interest rates being as high as they are.

Still, I think I’m looking at a great buy. Sure, the gaze of the market may be centred on firms like Lloyds and Rolls-Royce, but I think AstraZeneca is the best stock of the three. I’d buy in today if I had the spare cash.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

John Fieldsend has positions in Lloyds Banking Group Plc and Rolls-Royce Plc. The Motley Fool UK has recommended GSK and Lloyds Banking Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is Tesla stock about to crash? Here’s what the charts say

Tesla stock has demonstrated incredible volatility in recent months, but there will almost certainly be more to come. Dr James…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

5 AIM stocks to consider buying for the long term

We asked our writers to share their best AIM-listed stocks to consider buying, featuring five very different businesses.

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Is the Rolls-Royce share price still undervalued in 2025?

After massive growth in the Rolls-Royce share price, Charlie Carman considers whether the FTSE 100 aerospace and defence stock is…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

How an investor could target a £43k lifelong passive income starting with just £5 a day

Harvey Jones says it's possible to build a high-and-rising passive income by investing small, regular sums in FTSE 100 shares.…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

£10,000 invested in Lloyds shares on 7 April is already worth…

After a dip in early April, Lloyds shares are back to their 30%+ year-to-date gain in 2025. And analysts are…

Read more »

Tariffs and Global Economic Supply Chains
US Stock

What I’d look to buy as the US stock market heads for the worst month since 1932

Jon Smith sifts through the US stock market to try and find some ideas that have fallen in value recently…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Growth Shares

Prediction: I think £1,000 invested in this UK stock could double by 2030

Jon Smith runs through a FTSE 250 stock with a market cap just over £1bn that he feels has the…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

With £10k in savings, here’s how an investor could target a second income of £500 a month

£10k in savings could be the foundation needed towards a powerful second income. Our writer details some steps necessary to…

Read more »